hydroxychloroquine has been researched along with Sarcoma, Epithelioid in 2 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The purpose of this study was to investigate whether combined treatment with the autophagy inhibitor: hydroxychloroquine (HCQ) and the autophagy inducer: sirolimus (rapamycin, Rapa) would reduce glucose utilization in sarcoma patients." | 5.20 | Double autophagy modulators reduce 2-deoxyglucose uptake in sarcoma patients. ( Chen, YK; Chi, KH; Chi, MS; Chung, CH; Huang, SC; Ko, HL; Lee, CY; Liao, KW; Yang, KL, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Negayama, T | 1 |
| Ishibashi, Y | 1 |
| Nakamura, O | 1 |
| Nomura, Y | 1 |
| Kaji, Y | 1 |
| Yamamoto, T | 1 |
| Chi, MS | 1 |
| Lee, CY | 1 |
| Huang, SC | 1 |
| Yang, KL | 1 |
| Ko, HL | 1 |
| Chen, YK | 1 |
| Chung, CH | 1 |
| Liao, KW | 1 |
| Chi, KH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma[NCT01842594] | Phase 2 | 13 participants (Actual) | Interventional | 2012-08-31 | Terminated (stopped due to Most patients completed only the primary objective (PET) and not went throught the secondary outcome (efficacy phase) of 8wks period.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A baseline whole-body [18F]-fluorodeoxyglucose(FDG) PET was performed before therapy initiation. Patients received 1 mg of Rapa and 200 mg of HCQ twice a day before a meal for 2 weeks. A second [18F]-FDG PET was performed after treatment completion. SUVs were calculated for all lesions. Regions of interest (ROI) were contoured to represent tumors (>2 cm) and organs (lungs, spleen, and liver) on all transaxial and coronal slices. ROIs were normalized for injection dose and body weight, and the maximum voxel value was recorded for each region or organ. The highest SUV measured with increased uptake was considered the SUVmax. Correlative diagnostic CT examinations were used for accurate localization of the lesions. The most intense uptake at baseline was identified as the index lesion and evaluated for treatment response. (NCT01842594)
Timeframe: 2 Weeks
| Intervention | percentage of the SUVmax Change (Mean) |
|---|---|
| Sirolimus and Hydroxychloroquine | -19.6 |
Number of Participants with Adverse Events. Toxicities parameters are according to the Nation Cancer Institute Common Terminology Criteria for Adverse Event, version 3.0. (NCT01842594)
Timeframe: 2 Weeks
| Intervention | participants (Number) |
|---|---|
| Sirolimus and Hydroxychloroquine | 3 |
1 trial available for hydroxychloroquine and Sarcoma, Epithelioid
| Article | Year |
|---|---|
Double autophagy modulators reduce 2-deoxyglucose uptake in sarcoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophag | 2015 |
1 other study available for hydroxychloroquine and Sarcoma, Epithelioid
| Article | Year |
|---|---|
Rapalink-1 and Hydroxychloroquine Exhibit an Additive Effect in Undifferentiated Pleomorphic Sarcoma by Inducing Apoptosis.
Topics: Apoptosis; Autophagy; Cell Proliferation; Enzyme Inhibitors; Humans; Hydroxychloroquine; Sarcoma; Si | 2021 |